Meet Our New VP of Digital CMC Solutions: Industry Leader Christoph Pistek

QbDVision is thrilled to welcome Christoph Pistek to our leadership team as our new VP of Digital CMC Solutions. A leader in the pharmaceutical industry for over 20 years, Christoph comes to us from Takeda, where as Vice President, Head of Sustainability and Technology, Pharmaceutical Sciences, he worked on large-scale global innovation initiatives and advanced emerging capabilities and novel approaches in drug discovery and development.

Christoph brings extensive experience spanning pharmaceutical R&D, technical and supply operations, and business excellence, combining deep industry knowledge with engineering expertise and a track record in digital and organizational transformation.

The QbDVision team is thrilled to bring on such an adept industry practitioner who has direct experience implementing Digital CMC at scale, and will now bring that knowledge and expertise to the market.

Welcome, Christoph!

Building the Next Chapter in Digital CMC Solutions

Christoph is stepping into the newly created role of VP of Digital CMC Solutions, reflecting QbDVision's ambition to expand beyond its Digital CMC platform and services into broader, integrated solutions. Why this role, and why now?  Because Christoph has the knowledge and experience to help each organization find its starting point and drive large-scale digital transformation, starting from business outcomes, not technology.

“I feel digitization in CMC could be end-to-end already today,” Christoph says, “but navigating change is not easy. Too often, this change is run as a technology project. The organizations that get real value start from the business objective and own the transformation at the highest level.”

And as QbDVision Chief Business Officer Mike Stapleton notes, Christoph is the perfect person to help organizations navigate that change. “He knows how to do it. He's a visionary who brings firsthand experience in translating digital ambition into tangible business outcomes. He understands what it takes to move from strategy to execution, and how to make transformation work at scale.”

In his role, Christoph will focus not only on this long-needed technological shift, but on helping organizations develop the necessary strategies to put it into practice and working with them to actually implement those strategies.

{{pistek-announcement-q1}}

“We’ll be designing Digital CMC solutions that build on our platform and, where needed, go beyond it,” Christoph says. “For me, that means developing holistic transformation strategies and providing the platform and services to turn them into reality, across CMC organizations and their interfaces, with a strong focus on operational and technology excellence.”

These broader strategies are essential because of the outsized impact CMC has within organizations.

“CMC is the most complex intersection of product lifecycle data and knowledge,” he says. “We get inputs from research, manufacturing, quality, regulatory, and commercial. Few other functions have to share and interface that much. That’s why it’s so critical to understand the bigger picture, the whole value-stream and ecosystem.”

To Create Solutions, You Need to Know the Challenges

For Christoph, understanding the bigger picture starts with the business. Every pharma company shares the same fundamentals, but each has its own culture, objectives, and operating model. Understanding all of these is what allows solutions to deliver value across the enterprise, not just within a single function.

“We have to understand what we are going to enable,” he says. “We have to understand where the hot spots and bottlenecks are. We have to understand where the potential is to unlock benefits, to get rid of obstacles. And we have to connect business architecture to technology so that it's properly scalable and we can implement it."

Too often, Christoph says, the aim for perfection stops that work before it starts. “Organizations run another assessment, another RFI, another RFP, while the status quo gets locked in, costs keep climbing, and the landscape is shifting. At the end, they have a feature list and a gap analysis against an imagined, often already obsolete future state, but no business outcome. In that time, they could have delivered real value, and learned how their processes really need to change. That’s the hard part of transformation, and you only learn it by doing. The real risk isn’t getting it wrong. It’s doing nothing and learning nothing.”

Coming from the industry, Christoph is intricately familiar with the business problems he’s poised to help solve, but also eager to move beyond the typical use cases and push the boundaries of what’s possible.

{{pistek-announcement-q2}}

“We have to innovate beyond the obvious,” Christoph says. “QbDVision has one of the most exciting platforms in the industry, and I see tremendous opportunity to work with ambitious partners on use cases that can truly leapfrog today's CMC maturity and capabilities. By bringing together the right expertise, technologies, and partners, we can turn bold ideas into scalable solutions that fundamentally advance how our industry operates.”

Realizing the Industry’s Potential

So what excites Christoph about the future of the industry? One word: potential.

“There is so much potential in this industry. I think the pharmaceutical industry has some of the most tremendous talent I’ve ever met in my life. And if we have the ability to really maximize the impact of that talent, curiosity, and ingenuity, then we'll be getting towards a paradigm where we're not just providing treatments, but actually cures,” he says.

He also cites technology, specifically data and AI, as a means of unlocking that potential as well as democratizing treatments.

“We already have the technology and infrastructure. By using it to become more efficient and accelerate time to market, our industry has an opportunity to address a broader range of challenging and unmet medical needs. Technology can help make treatments more accessible, including for diseases and patient populations that have historically attracted less investment or commercial attention, what we have to do now is scale it. That's what makes me optimistic. I think there's just so much that can still be done.”

We think there is, too, and we can’t wait to tackle it together.

‍